CPHI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Home Market News Hikma Pharmaceuticals makes leadership and organisational changes to US business
News
26 Jun 2017

Hikma Pharmaceuticals makes leadership and organisational changes to US business

US business will be organized into two entities - a US Generics Division and a US Injectables Division.

Hikma Pharmaceuticals has announced the planned retirement of Michael Raya, CEO of the US business. Following the significant increase in scale during the last several years, Hikma has also announced organisational changes to the US business (West Ward Pharmaceuticals) as well as a number of senior leadership changes and appointments to reflect its enhanced US market positioning and to better align with the global Hikma organisation.

Key changes include the following:

  • Michael Raya, CEO of the US business will retire at the end of this year. Mr Raya has led the US business for more than 25 years and in that time, has demonstrated strong leadership that has enabled Hikma to grow into a top 10 generics company in the US.
  • From 1 July 2017, the US business will be organized into two entities both of which will report into the Chairman and CEO, Said Darwazah. There will be a US Generics Division and a US Injectables Division.
  • Brian Hoffmann has been promoted to President of the US Generics Division. Mr Hoffmann brings a wealth of experience in strategy, business development, M&A and marketing. Since joining West-Ward/Hikma in 2009, he has been instrumental in the growth of the US business.
  • Riad Mishlawi has been promoted to the role of CEO, Injectables Division, responsible for all injectable operations globally, including the newly formed US Injectables Division. Riad brings both breadth and depth to this role, having worked with the company since 1990 and led the Injectables Division through a period of rapid growth.
  • Mr Raya will continue to have oversight of the US business, working closely with the team for the rest of the year to transition the business.

    • “I would like to thank Mike for his many years of successful leadership of our US business, and wish him well in his retirement” said Said Darwazah, Chairman and CEO of Hikma. “The leadership and organisational changes we have announced today will bring greater organisational focus and alignment, establish a scalable structure to enable continued growth, and strengthen the US leadership team.”

    Commenting on his retirement, Mr Raya said, "Together with my colleagues, I am proud of what we were able to accomplish during my time at Hikma/West Ward and leave confident that the company is extremely well-positioned for the future."

    Related tags
    Market

    Related News